Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3C2B | O00750 | 19/20 | 0.59 |
| ▸ | PIK3CB | P42338 | 2/20 | 0.48 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.48 |
| ▸ | PIK3R1 | P27986 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1281753 | 0.93 | PIK3C2B (0.68) | PIK3C2BPIK3CBPIK3CDPIK3R1 | |
| SCHEMBL1282082 | 0.87 | PIK3C2B (0.75) | PIK3C2BPIK3CBPIK3CDPIK3R1 | |
| SCHEMBL1688058 | 0.86 | PIK3C2B (0.77) | PIK3C2BPIK3CBPIK3CDPIK3R1 | |
| SCHEMBL10184197 | 0.82 | PIK3C2B (0.62) | PIK3C2BPIK3CBPIK3CDPIK3R1 | |
| SCHEMBL1688053 | 0.82 | PIK3C2B (0.62) | PIK3C2BPIK3CBPIK3CDPIK3R1 | |
| SCHEMBL1688028 | 0.80 | PIK3C2B (0.86) | PIK3C2BPIK3CBPIK3CDPIK3R1 | |
| SCHEMBL1630617 | 0.79 | PIK3C2B (0.77) | PIK3C2BPIK3CBPIK3CDPIK3R1 | |
| SCHEMBL18887678 | 0.78 | PIK3C2B (0.68) | PIK3C2BPIK3CBPIK3CD | |
| SCHEMBL10186106 | 0.76 | PIK3C2B (0.56) | PIK3C2BPIK3CBPIK3CDPIK3R1 | |
| SCHEMBL1281671 | 0.75 | PIK3C2B (0.81) | PIK3C2BPIK3CBPIK3CD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120088767-A1 | BENZIMIDAZOLE DERIVATIVES AS PI3 KINASE INHIBITORS | GLAXOSMITHKLINE LLC | 2012-04-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120088767-A1 | BENZIMIDAZOLE DERIVATIVES AS PI3 KINASE INHIBITORS | PI4KB, PI4KA, PIK3CD | PIK3C2B 13/4885PIK3CB 4/4885PIK3CD 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.